There is increasing evidence suggesting a link exists between the gut immune system and several autoimmune diseases, including diabetes. The industrial partner of this project, enGene, has developed an effective non-viral based technology for the delivery of genes to the intestine. enGene has demonstrated the feasibility of delivering IL-10, which is an anti-inflammatory cytokine, to the intestine and showed therapeutic efficacy in inflammatory bowel disease.